^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

Published date:
05/19/2021
Excerpt:
Table summarizes matched therapies in responders....Sarcoma...SMARCB1: A240fs*28...Palbociclib – SD, 6 mo...Tazemetostat – SD, 2 yrs
DOI:
10.1200/JCO.2021.39.15_suppl.11538